Latest & greatest articles for irritable bowel syndrome

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on irritable bowel syndrome or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on irritable bowel syndrome and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for irritable bowel syndrome

181. Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials

Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Selective serotonin reuptake inhibitors for the management of irritable bowel syndrome: a meta-analysis of randomized controlled trials Rahimi R, Nikfar S, Abdollahi M CRD summary The authors stated (...) that there was no statistically significant evidence that selective serotonin reuptake inhibitors (SSRIs) improved abdominal pain, bloating or irritable bowel syndrome (IBS) symptoms, although there was a trend for improvement in abdominal pain. In view of methodological limitations in the review, in particular the failure to adequately address heterogeneity, the conclusions may not be reliable. Authors' objectives To determine the efficacy of selective serotonin reuptake inhibitors (SSRIs) for irritable bowel syndrome (IBS

2008 DARE.

182. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis Ford A C, Talley N J, Spiegel B M, Foxx-Orenstein A E, Schiller L, Quigley E M, Moayyedi P CRD (...) summary This review concluded that fibre, antispasmodics and peppermint oil are more effective than placebo for treating irritable bowel syndrome. Overall, although the review was generally well conducted, the authors' analyses should be interpreted with caution given their reliance on an often limited number of small and sometimes potentially quite different studies. Authors' objectives To compare the effectiveness of fibre, antispasmodics and peppermint oil with placebo or control for treating

2008 DARE.

183. The relationship between somatisation and outcome in patients with severe irritable bowel syndrome

The relationship between somatisation and outcome in patients with severe irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2008 NHS Economic Evaluation Database.

184. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. Full Text available with Trip Pro

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. To investigate whether placebo effects can experimentally be separated into the response to three components-assessment and observation, a therapeutic ritual (placebo treatment), and a supportive patient-practitioner relationship-and then progressively combined to produce incremental clinical improvement in patients with irritable bowel syndrome. To assess the relative magnitude

2008 BMJ Controlled trial quality: predicted high

185. Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting Full Text available with Trip Pro

Clinical trial: renzapride therapy for constipation-predominant irritable bowel syndrome--multicentre, randomized, placebo-controlled, double-blind study in primary healthcare setting Relatively few pharmacological treatment options are available for treating patients with irritable bowel syndrome. New and effective medicines are urgently required.To identify an appropriate dosage of renzapride (a 5-HT(4) receptor full agonist/5-HT(3) receptor antagonist) to treat abdominal pain/discomfort (...) to placebo. Renzapride was well tolerated at all doses.This study confirms the gastrointestinal prokinetic effects of renzparide. The data also suggested a potentially beneficial effect on abdominal pain/discomfort in women with constipation-predominant irritable bowel syndrome.

2008 EvidenceUpdates Controlled trial quality: predicted high

186. Hypnotherapy for Children With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Controlled Trial. (Abstract)

Hypnotherapy for Children With Functional Abdominal Pain or Irritable Bowel Syndrome: A Randomized Controlled Trial. BACKGROUND & AIMS: Functional abdominal pain (FAP) and irritable bowel syndrome (IBS) are highly prevalent in childhood. A substantial proportion of patients continues to experience long-lasting symptoms. Gut-directed hypnotherapy (HT) has been shown to be highly effective in the treatment of adult IBS patients. We undertook a randomized controlled trial and compared clinical

2007 EvidenceUpdates Controlled trial quality: uncertain

187. Hypnotherapy for treatment of irritable bowel syndrome. Full Text available with Trip Pro

Hypnotherapy for treatment of irritable bowel syndrome. Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder of unknown aetiology. Current pharmacological treatments have limited value. Hypnotherapy has been reported to have beneficial effects for IBS symptoms.To evaluate the efficacy of hypnotherapy for the treatment of irritable bowel syndrome.Published and unpublished randomised clinical trials and quasi-randomised clinical trials were identified through structured (...) for the treatment of irritable bowel syndrome with no treatment or another therapeutic intervention.All studies were evaluated for eligibility for inclusion. Included studies were assessed for quality and data were extracted independently by four authors. The primary outcome measure of interest was the overall bowel symptom severity score which combines abdominal pain, diarrhoea or constipation and bloating. Secondary outcomes included abdominal pain, diarrhoea, constipation, bloating, quality of life

2007 Cochrane

188. Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study

Economic evaluation of tegaserod vs placebo in the treatment of patients with irritable bowel syndrome: an analysis of the TENOR study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2007 NHS Economic Evaluation Database.

189. The efficacy of antidepressants and various psychotherapies as adjunctive treatments for irritable bowel syndrome (IBS).

The efficacy of antidepressants and various psychotherapies as adjunctive treatments for irritable bowel syndrome (IBS). Guidelines and Measures | Agency for Healthcare Research & Quality HHS.gov Search ahrq.gov Search ahrq.gov Menu Topics A - Z Healthcare Delivery Latest available findings on quality of and access to health care Searchable database of AHRQ Grants, Working Papers & HHS Recovery Act Projects AHRQ Projects funded by the Patient-Centered Outcomes Research Trust Fund You are here

2006 University of Texas at Austin School of Nursing, Family Nurse Practitioner Program

190. Herbal medicines for treatment of irritable bowel syndrome. Full Text available with Trip Pro

Herbal medicines for treatment of irritable bowel syndrome. Traditional herbal therapies have been used for a long time to treat gastrointestinal disorders including irritable bowel syndrome, and their effectiveness from clinical research evidence needs to be systematically reviewed.To assess the effectiveness and safety of herbal medicines in patients with irritable bowel syndrome.We searched the following electronic databases till July 2004: The Cochrane Library (CENTRAL), MEDLINE, EMBASE (...) of randomised participants.Seventy-five randomised trials, involving 7957 participants with irritable bowel syndrome, met the inclusion criteria. The methodological quality of three double-blind, placebo-controlled trials was high, but the quality of remaining trials was generally low. Seventy-one different herbal medicines were tested in the included trials, in which herbal medicines were compared with placebo or conventional pharmacologic therapy. Herbal medicines were also combined with conventional

2006 Cochrane

191. A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome

A randomised controlled trial of self-help interventions in patients with a primary care diagnosis of irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 NHS Economic Evaluation Database.

192. Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review

Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review Effectiveness of the Chinese herbal formula TongXieYaoFang for irritable bowel syndrome: a systematic review Bian Z, Wu T, Liu L, Miao J, Wong H, Song L, Sung J J CRD summary The review assessed the Chinese herbal medicine TongXieYaoFang for irritable bowel syndrome. The authors (...) concluded that TongXieYaoFang together with other Chinese medicinal herbs has the potential to improve symptoms of irritable bowel syndrome more than conventional medicines. It is highly likely that the evidence reviewed was biased towards results in favour of TongXieYaoFang. Authors' objectives To evaluate the effectiveness of TongXieYaoFang (TXYF) with or without additional Chinese herbal medicines for the management of irritable bowel syndrome (IBS). Searching MEDLINE, EMBASE, the Cochrane Controlled

2006 DARE.

193. Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome

Systematic review: the effectiveness of hypnotherapy in the management of irritable bowel syndrome Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

194. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial

Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial Kennedy T M, Chalder T, McCrone P, Darnley S, Knapp M, Jones R H, Wessely S (...) Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Kennedy T M, Chalder T, McCrone P, Darnley S, Knapp M, Jones R H, Wessely S. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: randomised controlled trial. Health Technology Assessment 2006; 10(19): 1-84 Authors' objectives The aim

2006 Health Technology Assessment (HTA) Database.

195. A self help guidebook reduced primary care consultations in irritable bowel syndrome

A self help guidebook reduced primary care consultations in irritable bowel syndrome A self help guidebook reduced primary care consultations in irritable bowel syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here A self help guidebook reduced primary care consultations in irritable bowel syndrome Article Text Therapeutics A self help guidebook reduced primary care consultations in irritable bowel syndrome Statistics from

2006 Evidence-Based Medicine

196. Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome Full Text available with Trip Pro

Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: soluble fibre improves overall symptoms and constipation but not abdominal pain in irritable bowel syndrome Article Text Therapeutics Review: soluble fibre

2005 Evidence-Based Medicine

197. Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action

Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action Hypnosis and irritable bowel syndrome: a review of efficacy and mechanism of action Tan G, Hammond D C, Gurrala J CRD summary This review concluded that variations on a protocol for hypnosis represent an effective therapy for reducing symptoms of irritable bowel syndrome and improving emotional and quality-of-life outcomes (...) in the long term. Several significant limitations in the review process, along with the paucity of the evidence reviewed, suggest that the authors' conclusions may be overstated and not particularly robust. Authors' objectives To assess the efficacy of hypnosis in reducing the symptoms and in improving emotional and quality-of-life outcomes associated with irritable bowel syndrome (IBS), and to examine the possible mechanisms of action. Searching The authors searched PubMed and PsycLIT, along with medical

2005 DARE.

198. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. Full Text available with Trip Pro

Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. To assess the efficacy of cognitive behaviour therapy delivered in primary care for treating irritable bowel syndrome.Randomised controlled trial.10 general practices in London.149 patients with moderate or severe irritable bowel syndrome resistant to the antispasmodic mebeverine.Cognitive behaviour therapy delivered by trained primary care nurses plus (...) 270 mg mebeverine taken thrice daily compared with mebeverine treatment alone.Primary measures were patients' scores on the irritable bowel syndrome symptom severity scale. Secondary measures were scores on the work and social adjustment scale and the hospital anxiety and depression scale.Of 334 referred patients, 72 were randomised to mebeverine plus cognitive behaviour therapy and 77 to mebeverine alone. Cognitive behaviour therapy had considerable initial benefit on symptom severity compared

2005 BMJ Controlled trial quality: predicted high

199. Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Full Text available with Trip Pro

Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Psychotherapy or paroxetine did not reduce abdominal pain, but may improve quality of life in irritable bowel syndrome Article Text Economics

2004 Evidence-Based Medicine

200. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. Full Text available with Trip Pro

Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. Irritable bowel syndrome (IBS), which affects 11% to 14% of the population, is a puzzling condition with multiple models of pathophysiology including altered motility, visceral hypersensitivity, abnormal brain-gut interaction, autonomic dysfunction, and immune activation. Although no conceptual framework accounts for all the symptoms and observations in IBS, a unifying explanation may exist since 92 (...) between the pattern of bowel movement and the type of excreted gas, a prevalence of abnormal lactulose breath test in 84% of IBS patients, and a 75% improvement of IBS symptoms after eradication of SIBO. Altered gastrointestinal motility and sensation, changed activity of the central nervous system, and increased sympathetic drive and immune activation may be understood as consequences of the host response to SIBO.The gastrointestinal and immune effects of SIBO provide a possible unifying framework

2004 JAMA